Tumor-vascular interactions and tumor dormancy

APMIS

Volumn 116, Issue 7-8, 2008, Pages 569-585

  Naumov, George N ^a,b   Folkman, Judah ^a,b   Straume, Oddbjorn ^a,b,c   Akslen, Lars A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Angiogenesis; Animal model; Dormancy; Human tumors; Metastasis; Occult cancer; Trauma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; SUNITINIB;

ANGIOGENESIS; APOPTOSIS; AUTOPSY; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; DORMANCY; HUMAN; METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; THYROID CARCINOMA; TUMOR DORMANCY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 52049085269     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.01213.x     Document Type: Review

References (121)

1. Naumov GN, Folkman J. Strategies to prolong the nonangiogenic dormant state of human cancer. In: Davis DW, Herbst RS, Abbruzzese JL, editors. Antiangiogenic Cancer Therapy. Boca Raton, FL : CRC Press, 2008 3 21.
2. Institute NC Surveillance Epidemiology and End Results (SEER) database : Web page]// April 15, 2008; Available from: http: //seer.cancer.gov/.
3. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993 328 : 1237 43.
4. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chang CF, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000 38 : 625 51.
5. Larsen I, Smastuen M, Parkin D, Bray F. Cancer in Norway 2006. Cancer incidence, mortality, survival and prevalence in Norway. Oslo : Cancer Registry of Norway, 2007.
6. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007 8 : 1129 38.
7. Jonsson H, Johansson R, Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005 117 : 842 7.
8. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004 328 : 921 4.
9. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987 56 : 814 9.
10. Kramer WM, Rush BF Jr. Mammary duct proliferation in the elderly. A histopathologic study. Cancer 1973 31 : 130 7.
11. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985 16 : 796 807.
12. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985 51 : 271 8.
13. Ryan JA, Coady CJ. Intraductal epithelial proliferation in the human breast - a comparative study. Can J Surg 1962 5 : 12 9.
14. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987 60 : 2751 60.
15. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985 56 : 531 8.
16. Mortensen JD, Bennett WA, Woolner LB. Incidence of carcinoma in thyroid glands removed at 1000 consecutive routine necropsies. Surg Forum 1955 5 : 659 63.
17. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol 2005 26 : 87 90.
18. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989 64 : 547 51.
19. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 1974 34 : 2072 6.
20. Mitselou A, Vougiouklakis TG, Peschos D, Dallas P, Boumba VA, Agnantis NJ. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions. Anticancer Res 2002 22 : 1777 80.
21. Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. Cancer 1981 47 : 319 23.
22. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980 65 : 311 6.
23. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994 8 : 439 43.
24. Stamatiou K, Alevizos A, Agapitos E, Sofras F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate 2006 66 : 1319 28.
25. Stemmermann GN, Nomura AM, Chyou PH, Yatani R. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomarkers Prev 1992 1 : 189 93.
26. Shiraishi T, Watanabe M, Matsuura H, Kusano I, Yatani R, Stemmermann GN. The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo 1994 8 : 445 7.
27. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol 2005 48 : 739 44.
28. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977 20 : 680 8.
29. Montie JE, Wood DP Jr., Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989 63 : 381 5.
30. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005 174 : 1785 8 discussion 1788.
31. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994 86 : 45 8.
32. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996 41 : 177 85.
33. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven inter-ruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007 4 : 699 710.
34. Gao F, Tan SB, Machin D, Wong NS : Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res 2007 9 : R21.
35. Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat Epub ahead of print JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003 4 : 760 8.
36. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis [Epub]// ahead of print.
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
38. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 : 1182 6.
39. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 82 : 4 6.
40. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007 6 : 273 86.
41. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 : 58 61.
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 : 353 64.
43. Torres Filho IP, Leunig M, Yuan F, Intaglietta M, Jain RK. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci USA 1994 91 : 2081 5.
44. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005 218 : 1 14.
45. Greene HSN. Heterolgous transplantation of mammalian tumors. J Exp Med 1941 73 : 461 86.
46. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966 164 : 491 502.
47. Gimbrone MA Jr., Aster RH, Cotran RS, Corkery J, Jandl JH, Folkman J. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 1969 222 : 33 6.
48. Gimbrone MA Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972 136 : 261 76.
49. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996 32A : 2386 93.
50. Achilles EG, Fernandez A, Allred EN, Kisker O, Udagawa T, Beecken WD, et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001 93 : 1075 81.
51. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. Faseb J 2006 20 : 947 9.
52. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006 98 : 316 25.
53. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006 5 : 1779 87.
54. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999 147 : 89 104.
55. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001 12 : 863 79.
56. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003 63 : 1684 95.
57. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007 7 : 834 46.
58. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. Faseb J 2002 16 : 1361 70.
59. Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res 1986 46 : 1015 29.
60. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999 286 : 1358 62.
61. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995 55 : 4575 80.
62. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990 87 : 6624 8.
63. Sheibani N, Frazier WA. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett 1996 107 : 45 52.
64. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000 5 : 24 33.
65. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity torepress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003 3 : 219 31.
66. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994 265 : 1582 4.
67. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997 14 : 1495 502.
68. Chandrasekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, Roberts DD. Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell 2000 11 : 2885 900.
69. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998 101 : 982 92.
70. Volpert OV. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. Cancer Metastasis Rev 2000 19 : 87 92.
71. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D, et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. Embo J 1994 13 : 5668 78.
72. Dejong V, Degeorges A, Filleur S, Ait-Si-Ali S, Mettouchi A, Bornstein P, et al. The Wilms'tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene 1999 18 : 3143 51.
73. Slack JL, Bornstein P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ 1994 5 : 1373 80.
74. Tikhonenko AT, Black DJ, Linial ML. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 1996 271 : 30741 7.
75. Janz A, Sevignani C, Kenyon K, Ngo CV, Thomas-Tikhonenko A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 2000 28 : 2268 75.
76. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994 54 : 649 52.
77. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006 313 : 968 71.
78. Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998 17 : 819 24.
79. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001 1 : 46 54.
80. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science 1985 230 : 676 8.
81. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990 248 : 1656 60.
82. Morihara K, Takenaka H, Morihara T, Kishimoto S. Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar. J Am Acad Dermatol 2007 57 (5 Suppl S103 5.
83. Kotzen RM, Swanson RM, Milhorat TH, Boockvar JA. Post-traumatic meningioma: case report and historical perspective. J Neurol Neurosurg Psychiatry 1999 66 : 796 798.
84. Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JR. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol 2005 31 : 29 37.
85. Gamatsi IE, McCulloch TA, Bailie FB, Srinivasan JR. Malignant melanoma in a skin graft: burn scar neoplasm or a transferred melanoma? Br J Plast Surg 2000 53 : 342 4.
86. Flook D, Horgan K, Taylor BA, Hughes LE. Surgery for malignant melanoma: from which limb should the graft be taken? Br J Surg 1986 73 : 793 5.
87. Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF. The influence of surgical trauma on experimental metastasis. Cancer 1989 64 : 2035 44.
88. Murthy MS, Summaria LJ, Miller RJ, Wyse TB, Goldschmidt RA, Scanlon EF. Inhibition of tumor implantation at sites of trauma by plasminogen activators. Cancer 1991 68 : 1724 30.
89. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001 88 : 167 74.
90. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001 20 : 8334 41.
91. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 1999 79 : 1392 8.
92. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer 1996 32A : 1876 87.
93. Withers HR, Lee SP. Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 2006 16 : 111 9.
94. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979 39 : 1552 62.
95. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996 14 : 2197 205.
96. Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E, et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci USA 2006 103 : 4216 21.
97. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002 2 : 727 39.
98. Bouck N. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 1990 2 : 179 85.
99. O'Reilly M, Rosenthal R, Sage HE, Smith S, Holmgren L, Moses M, et al. The suppression of tumor metastases by a primary tumor. Surg Forum 1993 44 : 474 6.
100. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995 1 : 149 53.
101. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000 408 : 869 73.
102. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994 79 : 315 28.
103. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998 101 : 1055 63.
104. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996 2 : 689 92.
105. Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998 4 : 286 95.
106. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002 62 : 1931 4.
107. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998 95 : 3609 14.
108. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 151 : 1523 30.
109. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002 416 : 279 80.
110. Moscow J, Schneider E, Sikic BI, Morrow CS, Cowan KH. Drug resistance and its clinical circumvention. In: Kufe DW, Bast RC, Hite WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Cancer Medicine. Hamilton : BC Decker Inc., 2006 630 47.
111. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997 390 : 404 7.
112. Naumov GN, Beaudry P, Bender ER, Zurakowski D, Watnick R, Almog N, et al. Clinical and Experimental Metastasis. International Congress of the Metastasis Research Society, Springer 2004 636.
113. Harper J, Naumov GN, Exarhopoulos A, Bender E, Louis G, Folkman J, Moses MA. Predicting the switch to the angiogenic phenotype in a human tumor model. In: Proceedings of the American Association for Cancer Research 2006 837.
114. Klement G, Kikuchi L, Kieran M, Almog N, Yip TT, Folkman J : Early tumor detection using platelet uptake of angiogenesis regulators. Blood 2004 104 : 239a.
115. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008 111 : 1201 7.
116. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003 63 : 8345 50.
117. Italiano JE Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008 111 : 1227 33.
118. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969 48 : 963 74.
119. Italiano JE, Hartwig JH. Megakaryocyte development and platelet formation. In: Michelson AD. Platelets. Boston : Academic Press, 2002 21 36.
120. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006 354 : 2034 45.
121. Folkman J, Kalluri R : Cancer without disease. Nature 2004 427 : 787.